Frank Porreca, PhD, associate head of the Department of Pharmacology in the College of Medicine – Tucson, was one of the authors of an article published in JAMA Neurology that refers to medication that targets CGRP or its receptors. CGRP is an inflammatory neuropeptide that contributes significantly to the development of migraine attacks.